Objective: To better understand cross-sectional relationships between CSF and PET measures of tau pathology, we compared regional and global measures of 18 F-T807 (AV-1451) PET to CSF protein levels of total tau (t-tau), phosphorylated tau (p-tau), and b-amyloid 1-42 (Ab42).
Accumulations of b-amyloid (Ab) and intracellular tau are defining characteristics of Alzheimer disease (AD) pathology. CSF assays of Ab 1-42 (Ab42), total tau (t-tau), and tau phosphorylated at residue 181 (p-tau) proteins are commonly used tools for identifying individuals harboring AD pathology. These CSF-based assays are increasingly being supplemented with imaging biomarkers reflecting molecular pathology in vivo. Following the initial description of 11 C Pittsburgh compound B (PiB), 1 PET-based measures of amyloid pathology have come into increasing use in research and clinical settings. Several groups have demonstrated that PET measures of amyloid burden correlate well with CSF Ab42 measurements, and can be used in concert with other biomarkers as predictors of impending cognitive decline. [2] [3] [4] More recently, several promising PET radioligands for in vivo imaging of pathologic deposits of tau have been described. [5] [6] [7] [8] As postmortem neurofibrillary tangle (NFT) burden is a predictor of global cognition 9 and CSF t-tau 10 and p-tau 11 improve the sensitivity and specificity of CSF Ab42 alone to identify those likely to progress to AD dementia, 2 in vivo imaging of tau pathology may represent a useful biomarker in clinical and translational AD research. 18 F-T807 (T807, also known as 18 F AV1451) is a radioligand with high selectivity for pathologic tau aggregates (especially NFT pathology 5, 12 ) over amyloid plaques, limited nonspecific white and gray matter binding, 5 and circumscribed off-target binding. 12 Early experience with T807 demonstrates that ligand binding is increased in individuals with cognitive impairment. 5, 13 The spatial pattern of T807 binding in these early studies conforms with the distribution of NFT pathology seen in histopathologic studies in AD and in cognitively normal older individuals. 13 In the present study, we examine the relationship between commonly used CSF biomarkers of AD pathology and regional measures of T807 binding in a group of well-characterized, cognitively normal elderly (CNE) participants in order to better validate T807 PET as an imaging biomarker of tau pathology. METHODS Participants. Thirty-one elderly participants were recruited from the Harvard Aging Brain (HAB) study, a longitudinal examination of cognitive aging and preclinical AD based at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital in Boston, Massachusetts (table 1) . At enrollment in HAB, all participants underwent comprehensive medical and neurologic evaluation, and were excluded if a major medical, neurologic, psychiatric, or substance abuse-related illness was present. All participants were assessed as cognitively normal at enrollment in HAB, with global Clinical Dementia Rating 14 score of 0.0, Mini-Mental State Examination (MMSE) score of 27-30 (education-adjusted), and within 1.5 SD of education-adjusted norms for the Logical Memory 15 delayed paragraph recall portion of the Wechsler Memory Scale-Revised. 16 Standard protocol approvals, registrations, and patient consents. Study protocols and procedures were approved by the Partners Human Research Committee. All participants provided written, informed consent prior to completion of any study procedures.
PET image acquisition and processing. All PET data were acquired using a Siemens/CTI (Knoxville, TN) ECAT HR1 scanner (3D mode, 63 image planes, 15.2 cm axial field of view, 5.6 mm transaxial resolution, and 2.4 mm slice interval) at MGH. Both 11 C-PiB and 18 F-T807 were produced on-site using previously published protocols. 17 11 C-PiB PET data were acquired following an 8.5-15 mCi bolus injection followed immediately by a 60-minute dynamic acquisition in 69 frames (12 3 15 seconds, 57 3 60 seconds). 11 C-PiB PET data used in the present study are distribution volume ratios (DVR) derived from a cortical composite comprised of frontal, parietal, retrosplenial, and lateral temporal cortical regions (FLR 18 ). T807 PET was acquired 80-100 minutes after a 10.0 6 1.0 mCi bolus injection in 4 3 5-minute frames using previously published protocols. 13, 18 PET data were reconstructed and attenuation corrected, and each frame was evaluated to verify adequate count statistics and absence of head motion.
PET images were coregistered to structural images using rigid body registration as implemented in the SPM8 coreg function (Wellcome Department of Cognitive Neurology, London, UK). FreeSurfer (v5.1; http://surfer.nmr.mgh.harvard.edu)-defined cerebellar gray matter was used as a reference region to yield standardized uptake value ratios (SUVR) for T807 and DVR for PiB imaging. T807 SUVR in FreeSurfer-defined regions of interest (ROIs) averaged across both hemispheres was used to assess relationships with CSF biomarkers. Based on prior data describing regional distribution of tau NFT pathology in AD, 9 ROIs spanning early, middle, and late sites of tau deposition were chosen for analyses (table 2) . 19, 20 In addition to these 9 ROIs, FreeSurfer-defined total cerebral cortex ROI (both hemispheres) was used as a total cortical summary measure of T807 signal. Eight of 9 chosen ROIs consisted of 1 FreeSurfer region averaged across both hemispheres; the ninth, the Broca ROI, combined 2 FreeSurfer ROIs (pars opecularis and pars triangularis) averaged across hemispheres. PET data were not partial volume-corrected. as described previously, using FreeSurfer for automated segmentation. 13, 21 Lumbar puncture and CSF protein quantification. Following an overnight fast, 10-15 mL of CSF was collected using Quincke or Sprotte 22G-24G spinal needles. CSF was immediately centrifuged and stored at 280 8 C until protein quantification. T-Tau, p-tau, and Ab42 protein levels were determined via AlzBio3 (Fujirebio, Seguin, TX), a multiplexed immunoassay with fluorometric quantitation (xMAP), using previously described protocols. 22 Due to the addition of T807 imaging well after the start of the HAB study, CSF was obtained an average of 2.03 years prior to T807 imaging (figure e-1 at Neurology.org). This delay was examined as a potential covariate in statistical models, and did not significantly contribute to models predicting regional T807 SUVR with CSF protein measures.
Vertex-wise cortical analysis. 1 . Nine ROIs and a total cortical ROI were selected for comparison to CSF, based on prior reports. 13, 19, 20 Consonant with a previous study from our group, 13 temporal lobe regions (both neocortical and limbic) showed the highest T807 binding in these CNE individuals (tables 1 and 2). Within the temporal neocortex, progressively lower T807 SUVR was seen when moving from the Abbreviations: Ab42 5 b-amyloid 1-42; p-tau 5 phosphorylated tau; ROI 5 region of interest; t-tau 5 total tau. Corrected for sex and age. a p # 0.05.
Figure 1
Mean T807 standardized uptake value ratio (SUVR) in FreeSurferdefined regions of interest (ROIs)
FreeSurfer automated segmentation was used to identify ROIs for analysis. To illustrate the global pattern of T807 signal, the mean value for each FreeSurfer ROI is shown, with lighter colors indicating higher mean binding.
inferior to middle to superior temporal ROIs (figure 1 and table 2).
CSF t-tau and p-tau. Total cortical T807 SUVR significantly correlated with p-tau but not t-tau (table 2  and figure 2A) . Stronger correlations were observed between CSF and T807 SUVR in temporal lobe regions with relatively high levels of signal as compared to the total cortical ROI signal ( figure 1 and table 2) . Among limbic regions of the temporal lobe, entorhinal and parahippocampal T807 binding significantly correlated with CSF t-tau and p-tau (table 2 and figure 2B). T807 binding in the temporal pole correlated significantly with p-tau and at trend level with t-tau. T807 SUVR in the inferior temporal neocortex (ITC) and middle temporal neocortex (MTC) significantly correlated with both t-tau and p-tau ( figure  2C and table 2 ). Superior temporal cortical T807 SUVR was significantly correlated with p-tau, but not with t-tau. Except for a marginally significant relationship between p-tau and inferior parietal T807 SUVR (partial r 5 0.38, p 5 0.042), all selected ROIs showing significant correlations with CSF protein levels were within the temporal lobe in this sample of unimpaired participants. The peak correlation between CSF tau measures and T807 SUVR was seen in the ITC (p-tau: partial r 5 0.73; p , 0.001).
To confirm that our choice of ROIs was appropriate for the topography of T807 and range of CSF protein values in this sample, we also performed an exploratory, vertex-wise, whole brain analysis ( figure e-2) . The majority of vertices showing strong correlations between PET and p-tau were in the medial and lateral temporal lobes, though small clusters of correlated vertices were also observed along the posterior midline. This pattern fits well with the prior observation that T807 in temporal ROIs was more highly correlated with CSF measures of t-tau and p-tau than T807 SUVR in frontal and parietal ROIs, and validates the choice of ROIs for this sample.
CSF Ab42 and amyloid burden as measured by PET.
Lower CSF Ab42 significantly correlated with higher T807 SUVR in temporal neocortical (ITC, MTC, superior temporal cortex) but not limbic regions (entorhinal, parahippocampal, temporal pole; table 2 and figure 2, B and C). CSF Ab42 was a trend-level predictor of total cortical T807 SUVR (table 2) . Examining interrelationships between CSF measures, we observed that Ab42 was correlated at trend level with p-tau (partial r 5 20.354, p 5 0.059) and not significantly correlated with t-tau (partial r 5 20.096, p 5 0.621). As expected based on prior studies, a negative correlation between CSF Ab42 and PiB FLR was observed (partial r 5 20.65, p , 0.001). Used continuously, PiB FLR significantly predicted total cortical T807 SUVR (partial r 5 0.380, p 5 0.042).
CSF cutpoints and T807. Prior work using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the same method of CSF protein quantification used in the present study (INNOTEST AlzBio3 xMAP platform) has identified optimal CSF cutpoints for separating individuals likely to progress from mild cognitive impairment (MCI) to AD dementia. 23 Two separate cutpoints were derived-t-tau: CSF Ab42 ratio .0.39 and CSF Ab42 ,192 pg/mL-and both were examined with respect to T807 SUVR in our sample ( figure 3) . The t-tau:CSF Ab42 ratio was significantly correlated with total cortical (partial r 5 0.40, p 5 0.03) and ITC T807 SUVR (partial r 5 0.62, p , 0.001). As expected in this cognitively normal sample, relatively few of the cognitively normal elderly participants in our sample were classified as having CSF in the pathologic range using these cutpoints (4 and 2 individuals for the t-tau:CSF Ab42 ratio and CSF Ab42 cutpoints, respectively). Both cutpoints reflected similar corresponding values for total cortical and inferior temporal T807 SUVR values in this sample ( figure 3) . DISCUSSION Comparison of CSF-based AD biomarkers to the pattern of binding in T807 PET is a key step in validating this novel radioligand. Utilizing data from 31 cognitively normal elderly participants across a series of ROIs that ranged from early to late sites of NFT pathology in AD, we observed that CSF measures of t-tau and p-tau significantly correlated with T807 SUVR in neocortical and limbic regions of the temporal lobe. P-tau was particularly well-correlated with T807 SUVR in temporal limbic and neocortical regions, including the entorhinal, parahippocampal, inferior, middle, and superior temporal cortex. Weaker relationships between T807 SUVR and CSF measures of tau were seen in parietal and frontal regions, as well as with a total cortical measure, consistent with the expectation that NFT pathology would be relatively limited to the temporal lobe in our unimpaired sample.
The peak correlation between p-tau and T807 SUVR (partial r 5 0.73 in the ITC) is similar to the observed correlation between CSF Ab42 and PiB FLR in this relatively small dataset (partial r 5 20.65). In addition, we observed that lower CSF Ab42 predicted higher T807 binding in temporal neocortical regions, suggesting cognitively normal individuals harboring a high amyloid burden may show increased tau pathology in these regions. In contrast, we did not observe a significant relationship between CSF Ab42 and T807 SUVR in limbic temporal regions in this dataset. Though a great deal more work in larger samples and in impaired populations is needed to examine this possible distinction, these results are consistent with the concept that high amyloid deposition may be more strongly associated with neocortical tau deposition as compared to tau deposition in limbic temporal regions.
Established cutpoints for the INNOVA AlzBio3 xMAP platform derived from the separation of ADNI MCI progressors vs nonprogressors were applied to this dataset. 23 Cutpoints using CSF Ab42 and t-tau:CSF Ab42 ratio yielded very similar corresponding ITC and total cortical T807 SUVR values. Focusing on the ITC, the T807 SUVR values that correspond to the CSF cutpoints reported by Shaw et al. 23 (1.28 and 1.26, reflecting the ratio and CSF Ab42 cutpoints, respectively) fit well with a recent report from our group in which separation between cognitively normal and MCI populations was seen in a similar range of T807 SUVR values. 13 However, as only a small number of our sample fell within the pathologic range using these previously described cutpoints, further study in more impaired individuals will be needed to better establish T807 SUVR values that correspond to these CSF cutpoints.
Taken together, the observed correlations between CSF measures of tau pathology and T807 SUVR support the use of T807 PET as an in vivo imaging tool to assess tau pathology. Unlike PET-based measures of amyloid pathology (which are often highly collinear across frontal, temporal, and parietal cortical regions), these data highlight that PET measures of tau pathology may need to be considered regionally rather than globally. Further, the regional focus may vary based on the severity of the presumed tau pathology in a particular study population, and may well differ in more impaired vs cognitively normal individuals. Going forward, further work will be needed to identify the most informative regional patterns of T807 binding to answer specific research questions, such as prediction of cognitive performance in impaired populations, and discrimination of individuals at high and low risk of progression to AD dementia. 
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